Mike Laptev / Shutterstock.com
The Pharmaceutical Research and Manufacturers of America (PhRMA) has voiced concerns about the US Food and Drug Administration’s (FDA’s) draft guidance on biosimilars, which it suggests if enacted, could have an impact on the safety of biosimilar products.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
PhRMA, FDA, biosimilars, Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product